{"id":55786,"date":"2026-01-29T16:50:33","date_gmt":"2026-01-29T08:50:33","guid":{"rendered":"https:\/\/flcube.com\/?p=55786"},"modified":"2026-01-29T16:50:34","modified_gmt":"2026-01-29T08:50:34","slug":"changchun-high-techs-firsekibart-filing-accepted-for-non-infectious-uveitis","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=55786","title":{"rendered":"Changchun High\u2011Tech&#8217;s Firsekibart Filing Accepted for Non\u2011Infectious Uveitis"},"content":{"rendered":"\n<p><strong>Changchun High &amp; New Technology Industries (Group) Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/000661:SHE\">SHE:\u202f000661<\/a>) announced that the <strong>National Medical Products Administration (NMPA)<\/strong> has accepted its clinical filing for <strong>firsekibart<\/strong>, a <strong>Category\u202f1 drug<\/strong>, for the treatment of <strong>non\u2011infectious uveitis<\/strong> using an <strong>IL\u20111\u03b2 monoclonal antibody (mAb)<\/strong> mechanism. If approved, firsekibart would be the first IL\u20111\u03b2 mAb globally approved for this indication.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-regulatory-status\">Drug Profile &amp; Regulatory Status<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Changchun High &amp; New Technology Industries (SHE:\u202f000661)<\/td><\/tr><tr><td><strong>Drug<\/strong><\/td><td>Firsekibart (IL\u20111\u03b2 monoclonal antibody)<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Non\u2011infectious uveitis<\/td><\/tr><tr><td><strong>Filing Status<\/strong><\/td><td>NMPA clinical filing accepted for review<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>Blocks IL\u20111\u03b2 binding to IL\u20111R, inhibiting downstream signaling pathways<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First IL\u20111\u03b2 mAb for non\u2011infectious uveitis globally<\/td><\/tr><tr><td><strong>Category<\/strong><\/td><td>Category\u202f1 drug (China)<\/td><\/tr><tr><td><strong>Pipeline<\/strong><\/td><td>Also in development for endometriosis, CTD\u2011ILD, sJIA; approved for acute gouty arthritis (2025)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-clinical-rationale-amp-market-opportunity\">Clinical Rationale &amp; Market Opportunity<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Unmet Need:<\/strong> Current standard of care for non\u2011infectious uveitis relies on <strong>anti\u2011TNF\u03b1 agents<\/strong>, but a significant portion of patients experience inadequate response or intolerance<\/li>\n\n\n\n<li><strong>Clinical Evidence:<\/strong> Anti\u2011IL\u20111\u03b2 mAbs have demonstrated favorable outcomes in refractory non\u2011infectious uveitis patients in existing research<\/li>\n\n\n\n<li><strong>Mechanism Advantage:<\/strong> IL\u20111\u03b2 inhibition offers a novel pathway distinct from TNF\u03b1 blockade, potentially addressing treatment\u2011resistant cases<\/li>\n\n\n\n<li><strong>Patient Population:<\/strong> Non\u2011infectious uveitis affects an estimated <strong>100,000\u2013150,000 patients<\/strong> in China, with limited therapeutic options<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-impact-amp-commercial-outlook\">Market Impact &amp; Commercial Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>China Ophthalmology Market:<\/strong> Valued at <strong>\u00a515\u202fbillion<\/strong> : (~US$2.1\u202fbillion) in 2025, growing at <strong>10% CAGR<\/strong> driven by biologic adoption<\/li>\n\n\n\n<li><strong>First\u2011Mover Advantage:<\/strong> Firsekibart would be the <strong>first\u2011in\u2011class<\/strong> IL\u20111\u03b2 inhibitor for uveitis, commanding premium pricing and market share<\/li>\n\n\n\n<li><strong>Pipeline Synergy:<\/strong> Success in uveitis could accelerate approvals in <strong>endometriosis, CTD\u2011ILD, and sJIA<\/strong>, creating a multi\u2011indication franchise<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project <strong>\u00a5800\u202fmillion\u20131.2\u202fbillion<\/strong> (US$110\u2013170\u202fmillion) peak annual sales for uveitis indication alone by 2030<\/li>\n\n\n\n<li><strong>Regulatory Pathway:<\/strong> Category\u202f1 status enables priority review; NMPA approval could come as early as <strong>2027<\/strong><\/li>\n\n\n\n<li><strong>Next Steps:<\/strong> Phase\u202fI trial initiation planned for <strong>Q2\u202f2026<\/strong>; global partnership opportunities under evaluation<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding clinical development timelines, regulatory pathways, and revenue projections for firsekibart. Actual results may differ due to clinical trial outcomes, competitive dynamics, and NMPA review processes.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u4f0f\u6b23\u5947\u62dc\u5355\u6297\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of \u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u4f0f\u6b23\u5947\u62dc\u5355\u6297\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.\"><\/object><a id=\"wp-block-file--media-6730f6f0-5f7a-40af-b38b-cd22a1e47f6d\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u4f0f\u6b23\u5947\u62dc\u5355\u6297\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\">\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u4f0f\u6b23\u5947\u62dc\u5355\u6297\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/\u957f\u6625\u9ad8\u65b0\uff1a\u5173\u4e8e\u5b50\u516c\u53f8\u4f0f\u6b23\u5947\u62dc\u5355\u6297\u6ce8\u5c04\u6db2\u5883\u5185\u751f\u4ea7\u836f\u54c1\u6ce8\u518c\u4e34\u5e8a\u8bd5\u9a8c\u7533\u8bf7\u83b7\u5f97\u53d7\u7406\u7684\u516c\u544a.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-6730f6f0-5f7a-40af-b38b-cd22a1e47f6d\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Changchun High &amp; New Technology Industries (Group) Inc. (SHE:\u202f000661) announced that the National Medical Products&#8230;<\/p>\n","protected":false},"author":1,"featured_media":55788,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[2929,90,1171],"class_list":["post-55786","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-changchun-high-new-technology-industries","tag-clinical-trial-filings","tag-she-000661"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Changchun High\u2011Tech&#039;s Firsekibart Filing Accepted for Non\u2011Infectious Uveitis - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE:\u202f000661) announced that the National Medical Products Administration (NMPA) has accepted its clinical filing for firsekibart, a Category\u202f1 drug, for the treatment of non\u2011infectious uveitis using an IL\u20111\u03b2 monoclonal antibody (mAb) mechanism. If approved, firsekibart would be the first IL\u20111\u03b2 mAb globally approved for this indication.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=55786\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Changchun High\u2011Tech&#039;s Firsekibart Filing Accepted for Non\u2011Infectious Uveitis\" \/>\n<meta property=\"og:description\" content=\"Changchun High &amp; New Technology Industries (Group) Inc. (SHE:\u202f000661) announced that the National Medical Products Administration (NMPA) has accepted its clinical filing for firsekibart, a Category\u202f1 drug, for the treatment of non\u2011infectious uveitis using an IL\u20111\u03b2 monoclonal antibody (mAb) mechanism. If approved, firsekibart would be the first IL\u20111\u03b2 mAb globally approved for this indication.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=55786\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-29T08:50:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-29T08:50:34+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2902-1.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55786#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55786\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Changchun High\u2011Tech&#8217;s Firsekibart Filing Accepted for Non\u2011Infectious Uveitis\",\"datePublished\":\"2026-01-29T08:50:33+00:00\",\"dateModified\":\"2026-01-29T08:50:34+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55786\"},\"wordCount\":361,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55786#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2902-1.webp\",\"keywords\":[\"Changchun High &amp; New Technology Industries\",\"Clinical trial filings\",\"SHE: 000661\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55786#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55786\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=55786\",\"name\":\"Changchun High\u2011Tech's Firsekibart Filing Accepted for Non\u2011Infectious Uveitis - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55786#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55786#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2902-1.webp\",\"datePublished\":\"2026-01-29T08:50:33+00:00\",\"dateModified\":\"2026-01-29T08:50:34+00:00\",\"description\":\"Changchun High & New Technology Industries (Group) Inc. (SHE:\u202f000661) announced that the National Medical Products Administration (NMPA) has accepted its clinical filing for firsekibart, a Category\u202f1 drug, for the treatment of non\u2011infectious uveitis using an IL\u20111\u03b2 monoclonal antibody (mAb) mechanism. If approved, firsekibart would be the first IL\u20111\u03b2 mAb globally approved for this indication.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55786#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=55786\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55786#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2902-1.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/2902-1.webp\",\"width\":1080,\"height\":608,\"caption\":\"Changchun High\u2011Tech's Firsekibart Filing Accepted for Non\u2011Infectious Uveitis\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=55786#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Changchun High\u2011Tech&#8217;s Firsekibart Filing Accepted for Non\u2011Infectious Uveitis\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Changchun High\u2011Tech's Firsekibart Filing Accepted for Non\u2011Infectious Uveitis - Insight, China&#039;s Pharmaceutical Industry","description":"Changchun High & New Technology Industries (Group) Inc. (SHE:\u202f000661) announced that the National Medical Products Administration (NMPA) has accepted its clinical filing for firsekibart, a Category\u202f1 drug, for the treatment of non\u2011infectious uveitis using an IL\u20111\u03b2 monoclonal antibody (mAb) mechanism. If approved, firsekibart would be the first IL\u20111\u03b2 mAb globally approved for this indication.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=55786","og_locale":"en_US","og_type":"article","og_title":"Changchun High\u2011Tech's Firsekibart Filing Accepted for Non\u2011Infectious Uveitis","og_description":"Changchun High & New Technology Industries (Group) Inc. (SHE:\u202f000661) announced that the National Medical Products Administration (NMPA) has accepted its clinical filing for firsekibart, a Category\u202f1 drug, for the treatment of non\u2011infectious uveitis using an IL\u20111\u03b2 monoclonal antibody (mAb) mechanism. If approved, firsekibart would be the first IL\u20111\u03b2 mAb globally approved for this indication.","og_url":"https:\/\/flcube.com\/?p=55786","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-29T08:50:33+00:00","article_modified_time":"2026-01-29T08:50:34+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2902-1.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=55786#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=55786"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Changchun High\u2011Tech&#8217;s Firsekibart Filing Accepted for Non\u2011Infectious Uveitis","datePublished":"2026-01-29T08:50:33+00:00","dateModified":"2026-01-29T08:50:34+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=55786"},"wordCount":361,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=55786#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2902-1.webp","keywords":["Changchun High &amp; New Technology Industries","Clinical trial filings","SHE: 000661"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=55786#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=55786","url":"https:\/\/flcube.com\/?p=55786","name":"Changchun High\u2011Tech's Firsekibart Filing Accepted for Non\u2011Infectious Uveitis - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=55786#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=55786#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2902-1.webp","datePublished":"2026-01-29T08:50:33+00:00","dateModified":"2026-01-29T08:50:34+00:00","description":"Changchun High & New Technology Industries (Group) Inc. (SHE:\u202f000661) announced that the National Medical Products Administration (NMPA) has accepted its clinical filing for firsekibart, a Category\u202f1 drug, for the treatment of non\u2011infectious uveitis using an IL\u20111\u03b2 monoclonal antibody (mAb) mechanism. If approved, firsekibart would be the first IL\u20111\u03b2 mAb globally approved for this indication.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=55786#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=55786"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=55786#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2902-1.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2902-1.webp","width":1080,"height":608,"caption":"Changchun High\u2011Tech's Firsekibart Filing Accepted for Non\u2011Infectious Uveitis"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=55786#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Changchun High\u2011Tech&#8217;s Firsekibart Filing Accepted for Non\u2011Infectious Uveitis"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/01\/2902-1.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55786","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=55786"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55786\/revisions"}],"predecessor-version":[{"id":55789,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/55786\/revisions\/55789"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/55788"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=55786"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=55786"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=55786"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}